https://novapharmanews.com/us/news/hfma-conference-affordability-friction-high-hospital-costs 2026-06-13T17:34:25.313Z NovaPharmaNews en 2026-06-13T08:04:51.564Z HFMA conference: Affordability was the focus, but fixes remained unclear https://novapharmanews.com/uploads/articles/hfma-conference-affordability-friction-high-hospital-costs.webp HFMA conference: Affordability was the focus, but fixes remained unclear https://novapharmanews.com/us/news/fda-draft-guidance-payor-communications-rules 2026-06-13T17:49:12.478Z NovaPharmaNews en 2026-06-13T06:06:40.933Z FDA Draft Guidance Updates Payor Communications Rules https://novapharmanews.com/uploads/articles/fda-draft-guidance-payor-communications-rules.webp FDA Draft Guidance Updates Payor Communications Rules https://novapharmanews.com/eu/news/mhra-targets-medicine-safety-with-new-ai-sandbox 2026-06-13T18:22:21.478Z NovaPharmaNews en 2026-06-13T04:44:06.348Z MHRA targets medicine safety with new AI sandbox https://novapharmanews.com/uploads/articles/mhra-targets-medicine-safety-with-new-ai-sandbox.webp MHRA targets medicine safety with new AI sandbox https://novapharmanews.com/eu/news/biocryst-new-orladeyo-data-real-world-evidence-hae 2026-06-13T18:22:18.800Z NovaPharmaNews en 2026-06-13T04:44:05.748Z BioCryst’s New ORLADEYO Data Adds Real-World HAE Evidence ORLADEYO, berotralstat, HAE, hereditary angioedema https://novapharmanews.com/uploads/articles/biocryst-new-orladeyo-data-real-world-evidence-hae.webp BioCryst’s New ORLADEYO Data Adds Real-World HAE Evidence https://novapharmanews.com/eu/news/ema-researchers-map-ai-research-priorities-across-the-medicines-lifecycle 2026-06-13T18:22:21.444Z NovaPharmaNews en 2026-06-13T04:44:04.934Z EMA researchers map AI research priorities across the medicines lifecycle https://novapharmanews.com/uploads/articles/ema-researchers-map-ai-research-priorities-across-the-medicines-lifecycle.webp EMA researchers map AI research priorities across the medicines lifecycle https://novapharmanews.com/us/news/alembic-tentative-fda-approval-generic-larotrectinib-capsules 2026-06-13T17:31:33.214Z NovaPharmaNews en 2026-06-13T01:03:15.888Z Alembic Wins Tentative FDA Nod for First Generic Larotrectinib Capsules larotrectinib, Vitrakvi, NTRK fusion–positive solid tumors, solid tumors https://novapharmanews.com/uploads/articles/alembic-tentative-fda-approval-generic-larotrectinib-capsules.webp Alembic Wins Tentative FDA Nod for First Generic Larotrectinib Capsules https://novapharmanews.com/eu/news/truqap-us-approval-pten-deficient-metastatic-prostate-cancer 2026-06-13T16:31:54.057Z NovaPharmaNews en 2026-06-13T00:35:26.866Z Truqap gains US approval in PTEN-deficient metastatic prostate cancer Truqap, capivasertib, lutetium Lu 177 vipivotide tetraxetan, Pluvicto, abiraterone, prednisone, prostate cancer, PTEN-deficient metastatic hormone-sensitive prostate cancer, prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer, mCRPC https://novapharmanews.com/uploads/articles/truqap-us-approval-pten-deficient-metastatic-prostate-cancer.webp Truqap gains US approval in PTEN-deficient metastatic prostate cancer https://novapharmanews.com/us/news/fda-clears-first-otc-cgm-for-children-dexcom-stelo 2026-06-13T18:40:00.814Z NovaPharmaNews en 2026-06-13T00:07:10.284Z FDA Clears First OTC CGM for Children: Dexcom Expands Stelo Stelo Glucose Biosensor System, diabetes https://novapharmanews.com/uploads/articles/fda-clears-first-otc-cgm-for-children-dexcom-stelo.webp FDA Clears First OTC CGM for Children: Dexcom Expands Stelo https://novapharmanews.com/us/news/fda-priority-review-belzutifan-pembrolizumab-adjuvant-renal-cell-carcinoma 2026-06-13T17:49:13.031Z NovaPharmaNews en 2026-06-12T22:11:11.101Z FDA priority review advances belzutifan plus pembrolizumab in adjuvant RCC belzutifan, Welireg, pembrolizumab, Keytruda, berahyaluronidase alfa-pmph, Keytruda Qlex, adjuvant renal cell carcinoma, advanced renal cell carcinoma, von Hippel-Lindau disease https://novapharmanews.com/uploads/articles/fda-priority-review-belzutifan-pembrolizumab-adjuvant-renal-cell-carcinoma.webp FDA priority review advances belzutifan plus pembrolizumab in adjuvant RCC https://novapharmanews.com/us/news/chile-warning-labels-on-food-new-evidence-efficacy-obesity-risk 2026-06-13T21:24:32.612Z NovaPharmaNews en 2026-06-12T22:11:10.232Z Chile warning labels on food: new evidence on efficacy and obesity risk diabetes https://novapharmanews.com/uploads/articles/chile-warning-labels-on-food-new-evidence-efficacy-obesity-risk.webp Chile warning labels on food: new evidence on efficacy and obesity risk https://novapharmanews.com/eu/news/duty-of-care-oncology-conferences-planetary-health-research 2026-06-13T11:31:22.948Z NovaPharmaNews en 2026-06-12T04:35:39.114Z Duty of care at oncology conferences spotlights planetary health research Oncology https://novapharmanews.com/uploads/articles/duty-of-care-oncology-conferences-planetary-health-research.webp Duty of care at oncology conferences spotlights planetary health research https://novapharmanews.com/us/news/socioeconomic-status-shapes-childrens-brain-development-study-finds 2026-06-13T18:25:27.274Z NovaPharmaNews en 2026-06-12T04:05:06.994Z Socioeconomic status shapes children’s brain development, study finds https://novapharmanews.com/uploads/articles/socioeconomic-status-shapes-childrens-brain-development-study-finds.webp Socioeconomic status shapes children’s brain development, study finds https://novapharmanews.com/eu/news/synthetic-real-world-data-oncology-trial-decision-making 2026-06-13T18:16:44.395Z NovaPharmaNews en 2026-06-12T01:11:57.842Z Synthetic real-world data reshapes oncology trial decision-making Oncology https://novapharmanews.com/uploads/articles/synthetic-real-world-data-oncology-trial-decision-making.webp Synthetic real-world data reshapes oncology trial decision-making https://novapharmanews.com/us/news/fda-bemotrizinol-sunscreen-regulatory-update 2026-06-13T11:30:49.993Z NovaPharmaNews en 2026-06-12T01:08:57.412Z FDA adds bemotrizinol to sunscreen rules, expanding U.S. UV filter options sunburn, skin cancer, skin aging https://novapharmanews.com/uploads/articles/fda-bemotrizinol-sunscreen-regulatory-update.webp FDA adds bemotrizinol to sunscreen rules, expanding U.S. UV filter options https://novapharmanews.com/us/news/biotech-coming-of-age-market-analysis 2026-06-13T20:16:28.454Z NovaPharmaNews en 2026-06-12T01:05:39.096Z Biotech coming of age: market analysis of a sector in transition https://novapharmanews.com/uploads/articles/biotech-coming-of-age-market-analysis.webp Biotech coming of age: market analysis of a sector in transition https://novapharmanews.com/eu/news/ema-approved-104-human-medicines-in-2025-what-changed 2026-06-13T13:18:08.435Z NovaPharmaNews en 2026-06-12T00:42:15.602Z EMA approved 104 human medicines in 2025: what changed denosumab, osteoporosis, bone https://novapharmanews.com/uploads/articles/ema-approved-104-human-medicines-in-2025-what-changed.webp EMA approved 104 human medicines in 2025: what changed https://novapharmanews.com/eu/news/ema-post-authorisation-guidance-evidence-gaps-10-years 2026-06-13T20:16:24.307Z NovaPharmaNews en 2026-06-12T00:42:14.850Z EMA Post Authorisation Guidance Faces Evidence Gaps After 10 Years https://novapharmanews.com/uploads/articles/ema-post-authorisation-guidance-evidence-gaps-10-years.webp EMA Post Authorisation Guidance Faces Evidence Gaps After 10 Years https://novapharmanews.com/us/news/fda-approves-vepdegestrant-veppanu-esr1-mutated-breast-cancer 2026-06-13T20:53:55.673Z NovaPharmaNews en 2026-06-11T22:11:00.437Z FDA approves Vepdegestrant (Veppanu) for ESR1-mutated breast cancer vepdegestrant, Veppanu, estrogen receptor-positive, HER2-negative breast cancer https://novapharmanews.com/uploads/articles/fda-approves-vepdegestrant-veppanu-esr1-mutated-breast-cancer.webp FDA approves Vepdegestrant (Veppanu) for ESR1-mutated breast cancer